Key Insights

Highlights

Treatment Research

2 treatments under study, led by Description Of Clinical Characteristic

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

Trial Status

Unknown2

Clinical Trials (2)

Research Network

Common Treatments

  • Description Of Clinical Characteristic1
  • Description And Analysis1

Active Sponsors

  • Hospices Civils de Lyon2

Top Investigators

Related Conditions

  • Autoimmune Encephalitis1
  • Herpetic Encephalitis1

Activity Timeline